National Oxygen Limited has scheduled a board meeting for Friday, January 30, 2026, to review and approve its unaudited financial results for the third quarter of fiscal year 2026. The announcement was made through a formal communication to BSE Limited on January 27, 2026, in compliance with regulatory requirements.

Meeting Details and Regulatory Compliance

The board meeting has been convened in accordance with Regulation 29 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda item focuses on the consideration and approval of the company's unaudited financial results for the quarter ended December 31, 2025.

Trading Window Restrictions

National Oxygen Limited has implemented trading window restrictions as part of its insider trading prevention measures. The company referenced its earlier communication dated December 25, 2025, which outlined the trading window closure protocol.

The trading restrictions are structured as follows:

• Closure Start Date: January 1, 2026
• Applicable Persons: Individuals specified under the company's Code of Conduct
• Closure Duration: Until 48 hours after the board meeting conclusion
• Regulatory Basis: SEBI (Prohibition of Insider Trading) Regulations, 2015

Company Background

National Oxygen Limited operates as an ISO 9001:2015 certified company specializing in the manufacturing of industrial and medical gases. The company's product portfolio includes liquid and gaseous oxygen, liquid and gaseous nitrogen, liquid and gaseous medical oxygen, and dissolved acetylene gas.

The company maintains its registered office in Chennai and operates three manufacturing facilities across Tamil Nadu and Puducherry, supporting its tagline "Breathing Life Into Industry."

Regulatory Communication

The formal notification was signed by Rajesh Kumar Saraf, Managing Director (DIN: 00007353), and submitted to BSE Limited under scrip code 507813. The communication ensures transparency and compliance with stock exchange listing requirements for the upcoming financial results disclosure.

F.L.Dadabhoy, R.F.Dadabhoy, and N.F.Dadabhoy have collectively increased their shareholding in National Oxygen Limited to 9.062% through an open market purchase completed on January 19, 2026. The acquisition was disclosed to the company and BSE Limited under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Acquisition Details

The three acquirers purchased 3,240 additional shares through open market transactions, representing 0.06425% of the company's total voting share capital. This strategic purchase increased their combined stake from the previous holding of 4,53,720 shares.

Shareholding Pattern Changes

The acquisition resulted in a significant change in the group's overall shareholding position in National Oxygen Limited. Their total holding has now crossed the 9% threshold, triggering mandatory disclosure requirements under SEBI regulations.

Company Information

National Oxygen Limited maintains its equity share capital at 50,42,385 shares with a face value of ₹10 each. The company's shares are listed on BSE Limited, and the total voting capital remained unchanged following this acquisition.

Regulatory Compliance

The acquirers have confirmed they do not belong to the promoter or promoter group of National Oxygen Limited. The disclosure was made in compliance with Regulation 29(1) and (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with formal intimation sent to both the company and BSE Limited on January 19, 2026.